TILT Biotherapeutics has raised $25.6 million in Series B funding to advance TILT-123, an oncolytic adenovirus engineered to enhance immune response against tumors, into Phase 2 trials for platinum-resistant ovarian cancer.
TILT Biotherapeutics presented Phase I clinical data at ESMO 2024, showcasing the potential of fully intravenous TILT-123 monotherapy in advanced solid cancers.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.